ABSTRACT
Exposure to certain chemicals prenatally and in childhood can impact development and may increase risk for attention-deficit/hyperactivity disorder (ADHD). Leveraging a larger set of literature searches conducted to synthesize results from longitudinal studies of potentially modifiable risk factors for childhood ADHD, we present meta-analytic results from 66 studies that examined the associations between early chemical exposures and later ADHD diagnosis or symptoms. Studies were eligible for inclusion if the chemical exposure occurred at least 6 months prior to measurement of ADHD diagnosis or symptomatology. Included papers were published between 1975 and 2019 on exposure to anesthetics (n = 5), cadmium (n = 3), hexachlorobenzene (n = 4), lead (n = 22), mercury (n = 12), organophosphates (n = 7), and polychlorinated biphenyls (n = 13). Analyses are presented for each chemical exposure by type of ADHD outcome reported (categorical vs. continuous), type of ADHD measurement (overall measures of ADHD, ADHD symptoms only, ADHD diagnosis only, inattention only, hyperactivity/impulsivity only), and timing of exposure (prenatal vs. childhood vs. cumulative), whenever at least 3 relevant effect sizes were available. Childhood lead exposure was positively associated with ADHD diagnosis and symptoms in all analyses except for the prenatal analyses (odds ratios (ORs) ranging from 1.60 to 2.62, correlation coefficients (CCs) ranging from 0.14 to 0.16). Other statistically significant associations were limited to organophosphates (CC = 0.11, 95% confidence interval (CI): 0.03-0.19 for continuous measures of ADHD outcomes overall), polychlorinated biphenyls (CC = 0.08, 95% CI: 0.02-0.14 for continuous measures of inattention as the outcome), and both prenatal and childhood mercury exposure (CC = 0.02, 95% CI: 0.00-0.04 for continuous measures of ADHD outcomes overall for either exposure window). Our findings provide further support for negative impacts of prenatal and/or childhood exposure to certain chemicals and raise the possibility that primary prevention and targeted screening could prevent or mitigate ADHD symptomatology. Furthermore, these findings support the need for regular review of regulations as our scientific understanding of the risks posed by these chemicals evolves.
Subject(s)
Attention Deficit Disorder with Hyperactivity , Attention Deficit Disorder with Hyperactivity/chemically induced , Humans , Child , Environmental Exposure/adverse effects , Female , Prenatal Exposure Delayed Effects , PregnancyABSTRACT
Measures of viremic exposure over time, including HIV viral copy-years or durable viremic suppression, may be more relevant measures of viral load exposure for comorbid outcomes and mortality than single time point viral load measures. However, there are many subjective decisions that go into creating a cumulative variable such as HIV viral copy-years, including the appropriate anchoring point to begin accumulating exposure, the handling of viral load levels below an assay's lower limit of detection (LLD), the handling of gaps in the viral load trajectory, and when to apply the log10 transformation (before or after the accumulation calculation). Different decisions produce different values for HIV viral copy-years, and such differences could impact inferences in subsequent analyses of relationships with outcomes. In this paper, we develop several HIV viral copy-years variables that are standardized across:â¢Anchoring pointâ¢Handling of viral loads measured below the LLD and missing viral load measuresâ¢Application of the log10 transformation. These standardized variables may be consistently used in analyses of longitudinal cohort data. We also define a supplementary dichotomous HIV viral load exposure variable that may be used in tandem, or alternatively to, the HIV viral copy-years variables.
ABSTRACT
Mammary fibromatosis is a rare neoplastic proliferation of fibroblastic cells. Usually seen in abdominal and extra-abdominal sites, it is rarely seen in the breast. Patients with mammary fibromatosis usually present with a firm palpable mass with or without dimpling and skin retraction-often mimicking breast carcinoma. Here, we present a case of mammary fibromatosis in a 49-year-old woman who presented with a palpable lump in her right breast. Mammography tomosynthesis revealed architectural distortion which was seen on ultrasonography as a hypoechoic area. The patient underwent a wire-guided excision where the histology of this specimen showed irregular spindle cell proliferation with hemosiderin deposition, confirming mammary fibromatosis. Further re-excision of margins revealed no evidence of residual fibromatosis, and the patient underwent subsequent surveillance mammograms to ensure there was no recurrence.
ABSTRACT
Rectal cancer metastasis to the breast is rare with around 19 cases reported in literature. It signifies diffuse disseminated disease or highly aggressive tumour, such that surgical intervention other than palliation has a limited role. We report a case of a 43-year-old with the above presentation. As the management differs and because of its rarity the importance of the diagnosis between primary and the metastatic breast cancer is imperative.
ABSTRACT
INTRODUCTION: Acute and delayed chemotherapy-induced nausea and vomiting (CINV) occurs in most patients who receive high-dose melphalan and significantly affects patients' quality of life during autologous stem cell transplantation. Faced with unsatisfactory results using an aprepitant-based regimen, an olanzapine-based regimen was initiated, with the hope of improving the incidence of acute and delayed CINV. A retrospective study was conducted to compare the effectiveness of olanzapine- versus aprepitant-based regimens for CINV prevention in adult hematopoietic stem cell recipients who received high-dose melphalan. PATIENTS AND METHODS: We compared olanzapine (n = 43) to aprepitant (n = 54) and fosaprepitant (n = 20). Olanzapine was given orally at 5 mg twice daily for 5 days, aprepitant was given at 125 mg on day -1 and 80 mg on days 0 and 1, and fosaprepitant was given at 150 mg on day -1. The dose of 2 concomitant drugs (dexamethasone and 5-hydroxytryptamine type 3 receptor antagonist) was similar in the 2 groups. Nausea prevention was the primary endpoint. A complete response using a composite index of no emesis and no use of rescue medications was the secondary endpoint. RESULTS: The results showed that olanzapine significantly reduced the number of patients who experienced acute (P < .0001) or delayed (P < .004) nausea and significantly reduced the use of rescue medications for acute-onset (P < .0046) and delayed-onset (P < .0001) CINV compared with aprepitant. CONCLUSION: Compared with fosaprepitant, olanzapine reduced the number of patients with acute (P < .0318) and delayed (P < .1519) nausea and reduced the need for rescue medications for acute-onset (P < .0643) and delayed-onset (P < .0024) CINV.
Subject(s)
Antiemetics/therapeutic use , Benzodiazepines/therapeutic use , Morpholines/therapeutic use , Multiple Myeloma/complications , Nausea/etiology , Nausea/prevention & control , Vomiting/etiology , Vomiting/prevention & control , Adult , Aged , Algorithms , Aprepitant , Disease Management , Female , Hematopoietic Stem Cell Transplantation , Humans , Induction Chemotherapy/adverse effects , Male , Melphalan/administration & dosage , Melphalan/adverse effects , Middle Aged , Multiple Myeloma/therapy , Myeloablative Agonists/administration & dosage , Myeloablative Agonists/adverse effects , Nausea/drug therapy , Olanzapine , Transplantation Conditioning , Treatment Outcome , Vomiting/drug therapySubject(s)
Coccidioidomycosis/epidemiology , Colon/microbiology , Cryptococcosis/epidemiology , Endemic Diseases , Histoplasmosis/epidemiology , Job Syndrome/epidemiology , Adolescent , Adult , Amphotericin B/administration & dosage , Antifungal Agents/administration & dosage , Child , Child, Preschool , Coccidioides/immunology , Coccidioidomycosis/diagnosis , Coccidioidomycosis/drug therapy , Colon/pathology , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Cryptococcus/immunology , Duodenal Ulcer/epidemiology , Female , Histoplasma/immunology , Histoplasmosis/diagnosis , Histoplasmosis/drug therapy , Humans , Itraconazole/administration & dosage , Job Syndrome/genetics , Male , Middle Aged , Mutation/genetics , STAT3 Transcription Factor/genetics , Treatment Outcome , Triazoles/administration & dosage , United StatesABSTRACT
BACKGROUND: Z0011 study suggests patients with minimal disease do not require axillary clearance. Exclusions include T3 tumours, mastectomy or neoadjuvant treatment. This study assessed the utility of pre-operative US-guided core biopsy of axillary nodes and its correlation with nodal macrometastases. METHODS: 247 women with breast cancer outside Z0011 criteria were reviewed retrospectively. Sensitivity and specificity of pre-operative axillary ultrasound and core biopsy compared to final histology was assessed by contingency tables. RESULTS: 75/247 patients had macrometastases. Ultrasound-axilla was 72% sensitive and 77% specific in predicting macrometastasis. The positive (PPV) and negative predictive value (NPV) was 58% and 86.4% respectively. Core-biopsy of axilla node, was 92.6% sensitive and 66.7% specific in detecting macrometastasis. PPV and NPV 79.4% and 86.7% respectively. CONCLUSION: Positive pre-operative ultrasound-guided core biopsy accurately predicts macroscopic involvement of axillary nodes. Selected patients outside Z0011 parameters can proceed to axillary clearance without sentinel node biopsy or risking overtreatment.
Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/therapy , Lymph Nodes/pathology , Lymph Nodes/surgery , Sentinel Lymph Node Biopsy/methods , Ultrasonography, Interventional , Adult , Aged , Aged, 80 and over , Axilla , Female , Humans , Image-Guided Biopsy , Lymph Node Excision , Lymphatic Metastasis , Middle Aged , Retrospective Studies , Sensitivity and SpecificitySubject(s)
AIDS-Related Opportunistic Infections/diagnosis , HIV Infections/diagnosis , HIV-1 , Lung/diagnostic imaging , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/diagnosis , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/drug therapy , Aged , Anti-Infective Agents/therapeutic use , Diagnosis, Differential , Dyspnea/etiology , Female , Fever/etiology , HIV Infections/complications , Humans , Lung/pathology , Oxygen/blood , Pneumonia, Pneumocystis/drug therapy , Pneumonia, Pneumocystis/microbiology , Radiography , Sweating , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic useABSTRACT
Infected aneurysms of the aorta were first described as a result of septic emboli or contiguous spread from bacterial endocarditis and are usually caused by Staphylococcus or Salmonella species. We report a case of Nocardia-associated infected aneurysm of the native suprarenal aorta in an immunocompromised host. Surgical management consisted of placement of an interposition cryopreserved aortic homograft. Nocardia asteroides was identified on a microbiology specimen of the aorta and both microbiology and pathology specimens of the splenic tissue. To the best of our knowledge, this represents the first carefully documented, unique case of a Nocardia-infected aneurysm treated with homograft interposition. In addition, pathologic and microbiologic data are included from the postmortem examination 10 months later.
Subject(s)
Aneurysm, Infected/surgery , Aortic Aneurysm/surgery , Nocardia Infections/complications , Nocardia asteroides , Opportunistic Infections/complications , Aneurysm, Infected/microbiology , Aortic Aneurysm/microbiology , Female , Humans , Immunocompromised Host , Middle Aged , Nocardia Infections/immunology , Nocardia Infections/surgery , Opportunistic Infections/immunology , Opportunistic Infections/surgerySubject(s)
Cryptococcosis/diagnosis , Cryptococcus/isolation & purification , Lung/pathology , Meningitis, Cryptococcal/diagnosis , Pneumonia/diagnosis , Sepsis/diagnosis , Blood Chemical Analysis , Bronchoalveolar Lavage , Bronchoalveolar Lavage Fluid/microbiology , Cryptococcosis/complications , Diagnosis, Differential , Dyspnea/etiology , Fatal Outcome , Female , Hematologic Tests , Humans , Lung/diagnostic imaging , Meningitis, Cryptococcal/complications , Middle Aged , Pneumonia/complications , Sepsis/complications , Tomography, X-Ray ComputedABSTRACT
Both human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) lead to chronic infection in a high percentage of persons, and an expanding epidemic of HIV-1-HCV coinfection has recently been identified. These individuals provide an opportunity for simultaneous assessment of immune responses to two viral infections associated with chronic plasma viremia. In this study we analyzed the breadth and magnitude of the CD8(+)- and CD4(+)-T-lymphocyte responses in 22 individuals infected with both HIV-1 and HCV. A CD8(+)-T-lymphocyte response against HIV-1 was readily detected in all subjects over a broad range of viral loads. In marked contrast, HCV-specific CD8(+)-T-lymphocyte responses were rarely detected, despite viral loads in plasma that were on average 1,000-fold higher. The few HCV-specific responses that were observed were relatively weak and limited in breadth. CD4-proliferative responses against HIV-1 were detected in about half of the coinfected subjects tested, but no proliferative response against any HCV protein was found in these coinfected persons. These data demonstrate a major discordance in immune responses to two persistent RNA viruses. In addition, they show a consistent and profound impairment in cellular immune responses to HCV compared to HIV-1 in HIV-1-HCV-coinfected persons.